Seagen Inc., Cell Line Development, Bothell, Washington, USA.
Bayer AG, Biologics Development, Wuppertal, Germany.
Biotechnol Prog. 2024 Jul-Aug;40(4):e3449. doi: 10.1002/btpr.3449. Epub 2024 Mar 13.
Cell line development (CLD) represents a complex but highly critical process during the development of a biological drug. To shed light on this crucial workflow, a team of BioPhorum members (authors) has developed and executed surveys focused on the activities and effort involved in a typical CLD campaign. An average of 27 members from different companies that participate in the BioPhorum CLD working group answered surveys covering three distinguishable stages of a standard CLD process: (1) Pre-transfection, including vector design and construction; (2) Transfection, spanning the initial introduction of vector into cells and subsequent selection and analysis of the pools; and (3) Single Cell Cloning and Lead Clone Selection, comprising methods of isolating single cells and confirming clonal origin, subsequent expansion and screening processes, and methods for identifying and banking lead clones. The surveys were very extensive, including a total of 341 questions split between antibody and complex molecule CLD processes. In this survey review, the authors interpret and highlight responses for antibody development and, where relevant, contrast complex molecule development challenges to provide a comprehensive industry perspective on the typical time and effort required to develop a CHO production cell line.
细胞系开发(CLD)是生物药物开发过程中一个复杂但非常关键的过程。为了深入了解这一关键工作流程,BioPhorum 的一组成员(作者)开发并执行了专注于典型 CLD 活动和投入的调查。来自参与 BioPhorum CLD 工作组的不同公司的平均 27 名成员回答了涵盖标准 CLD 过程三个可区分阶段的调查:(1)转染前,包括载体设计和构建;(2)转染,涵盖载体最初引入细胞以及随后的选择和池分析;以及(3)单细胞克隆和先导克隆选择,包括分离单细胞和确认克隆起源的方法、随后的扩增和筛选过程,以及鉴定和保存先导克隆的方法。调查非常广泛,包括总共 341 个问题,分为抗体和复杂分子 CLD 过程。在本次调查综述中,作者对抗体开发的回答进行了解释和重点突出,并在相关情况下将复杂分子开发挑战进行对比,提供了对开发 CHO 生产细胞系所需的典型时间和投入的全面行业视角。